Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.57 |
| ▸ | CES1 | P23141 | 8/20 | 0.57 |
| ▸ | CES2 | O00748 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 5/20 | 0.48 |
| ▸ | PPARD | Q03181 | 5/20 | 0.48 |
| ▸ | PPARA | Q07869 | 5/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927729 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL380746 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2934619 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL9449697 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2128149 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2935238 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2926268 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2935093 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL145805 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2937329 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115698252-A | Dairy product composition | 生物乳业公司 | 2023-02-03 | — | — | CN | claimed |
| CN-117241680-A | Composition for promoting lipolysis | 三得利控股株式会社 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023169713-A1 | COMPOSITION OR ASSOCIATION OF COMPOUNDS PREFERABLY FOR USE IN THE TREATMENT OF NERVOUS DISEASES IN PARTICULAR NEURODEGENERATIVE DISEASES, METHOD FOR THE PREPARATION OF SUCH COMPOSITION OR ASSOCIATION OF COMPOUNDS AND USES THEREOF. | PHARMACEUTICA SAN MARCO S.R.L. (IT) | 2023-09-14 | — | — | WO | disclosed |
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2023-04-20 | — | — | US | disclosed |
| CN-115698252-A | Dairy product composition | 生物乳业公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4114829-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2023-01-11 | — | — | EP | disclosed |
| CN-114276960-A | Use of pasteurised akkermansia for the treatment of metabolic disorders | 卢万天主教大学 | 2022-04-05 | — | — | CN | disclosed |
| CN-107864654-B | Novel peptides and peptide compositions for immunotherapy and methods for the generation of scaffolds for pancreatic and other cancers | 伊玛提克斯生物技术有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-114126664-A | Molecular feedback loop based on locked degradation determinants and methods of use thereof | 加利福尼亚大学董事会 | 2022-03-01 | — | — | CN | disclosed |
| CN-114096249-A | Pharmaceutical composition for nasal delivery | 奥瑞克索股份公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-3875452-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2021-09-08 | — | — | EP | disclosed |
| CN-111801093-A | Improved delivery systems for moieties including CBD-enhanced compositions, formulations, and chimeras | 雷米生物科学公司 | 2020-10-20 | — | — | CN | disclosed |
| CN-111603488-A | Use of akkermansia for the treatment of metabolic disorders | 卢万天主教大学 | 2020-09-01 | — | — | CN | disclosed |
| CN-104918626-B | Use of akkermansia for the treatment of metabolic disorders | 卢万天主教大学 | 2020-07-07 | — | — | CN | disclosed |
| CN-111175484-A | Diagnosis of neuroautoimmune diseases | 欧蒙医学实验诊断股份公司 | 2020-05-19 | — | — | CN | disclosed |
| US-20200129471-A1 | USE OF CANNABIS TO TREAT FIBROMYALGIA, METHODS AND COMPOSITIONS THEREOF | ONE WORLD CANNABIS LTD (IL) | 2020-04-30 | — | — | US | disclosed |
| CN-110869362-A | Modified class A GPCR binding compounds | 国立研究开发法人理化学研究所 | 2020-03-06 | — | — | CN | disclosed |
| US-20150083146-A1 | PERSONAL VAPORIZER LIQUID FOR EMULSIFYING OIL-SOLUBLE COMPOUNDS AND RESINS | Verso PV, LLC | 2015-03-26 | — | — | US | disclosed |
| WO-2015042589-A1 | PERSONAL VAPORIZER LIQUID FOR EMULSIFYING OIL-SOLUBLE COMPOUNDS AND RESINS | Verso PV, LLC (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20090099254-A1 | Method and Kit for Regulation of Microvascular Tone | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPA | FAAH 77/4885CES1 17/4885CES2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.